0.000USD0.000Pre-market 07/24, 09:30 (ET)
68.45BMarket Cap
15.35P/E TTM
Regeneron Pharmaceuticals Inc
REGN Balance Sheet
You can check out the annual or quarterly balance sheets of Regeneron Pharmaceuticals Inc here to evaluate the financial health, analyze fundamentals, and calculate key ratios for liquidity, leverage, and return on equity.
FAQs
Which balance sheet metrics matter most when analyzing REGN stock?
Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.
What is the difference between assets, liabilities, and shareholders' equity?
Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.
What is the difference between current and non-current items?
Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.
How Much Cash Does Regeneron Pharmaceuticals Inc Have?
In its most recent quarterly, Regeneron Pharmaceuticals Inc had 2.96B in cash and cash equivalents.
What Are Regeneron Pharmaceuticals Inc's Total Assets?
As of the latest reported quarter, Regeneron Pharmaceuticals Inc's total assets were 40.56B, consisting of 18.02B in current assets and 22.54B in non-current assets.
How Much Shareholders' Equity Does Regeneron Pharmaceuticals Inc Have?
Regeneron Pharmaceuticals Inc reported 31.26B in total shareholders' equity as of the latest reported quarter.